Evidence map›Paper›PMID 33562569›Full record

ArticleCells2021

The microRNA let-7b-5p Is Negatively Associated with Inflammation and Disease Severity in Multiple Sclerosis.

Georgia Mandolesi, Francesca Romana Rizzo, Sara Balletta, Mario Stampanoni Bassi, Luana Gilio, Livia Guadalupi, Monica Nencini, Alessandro Moscatelli, Colleen Patricia Ryan, Valerio Licursi and 17 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2023
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 1 country.

Georgia MandolesiSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
Francesca Romana RizzoDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Sara BallettaDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Mario Stampanoni BassiUnit of Neurology, IRCCS Neuromed, 86077 Pozzilli, Italy.
Luana GilioUnit of Neurology, IRCCS Neuromed, 86077 Pozzilli, Italy.
Livia GuadalupiSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
Monica NenciniSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
Alessandro MoscatelliDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0001-6269-4536
Colleen Patricia RyanDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0003-0298-5117
Valerio LicursiLaboratory of Functional Genomics and Proteomics of Model Systems, Department of Biology and Biotechnologies "C. Darwin," University of Rome "Sapienza", Rome 00185, Italy.
Ettore DolcettiDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Alessandra MusellaSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
Antonietta GentileSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
Diego FresegnaSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.ORCID 0000-0002-6943-1904
Silvia BullittaSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
Silvia CaioliUnit of Neurology, IRCCS Neuromed, 86077 Pozzilli, Italy.
Valentina VanniSynaptic Immunopathology Lab, IRCCS San Raffaele Pisana, 00166 Rome, Italy.
Krizia SannaDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Antonio BrunoDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0003-0976-3410
Fabio ButtariUnit of Neurology, IRCCS Neuromed, 86077 Pozzilli, Italy.
Chiara CastelliLaboratory of Functional Genomics and Proteomics of Model Systems, Department of Biology and Biotechnologies "C. Darwin," University of Rome "Sapienza", Rome 00185, Italy.
Carlo PresuttiLaboratory of Functional Genomics and Proteomics of Model Systems, Department of Biology and Biotechnologies "C. Darwin," University of Rome "Sapienza", Rome 00185, Italy.
Francesca De SantaInstitute of Biochemistry and Cell Biology (IBBC), National Research Council of Italy (CNR), 00015 Rome, Italy.
Annamaria FinardiNeuroimmunology Unit, Institute of Experimental Neurology (INSpe), Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.
Roberto FurlanNeuroimmunology Unit, Institute of Experimental Neurology (INSpe), Division of Neuroscience, San Raffaele Scientific Institute, 20132 Milan, Italy.ORCID 0000-0001-7376-9425
Diego CentonzeDepartment of Systems Medicine, Tor Vergata University, 00133 Rome, Italy.
Francesca De VitoUnit of Neurology, IRCCS Neuromed, 86077 Pozzilli, Italy.
University of Rome Tor Vergata · ITIstituto Neurologico Mediterraneo · ITIRCCS Ospedale San Raffaele · ITSapienza University of Rome · ITSan Raffaele University of Rome · ITNational Research Council · IT

Funding

Fondazione Italiana Sclerosi Multipla 2018/B/2Fondazione Italiana Sclerosi Multipla 2019/S/1 and financed and co-financed with the '5 per mille' public fundingItalian Ministry of Health GR-2016-02362380Italian Ministry of Health GR-2018-12366154Ministero della Salute GR-2016-02361163Ministero dell'Istruzione, dell'Università e della Ricerca MIUR-PRIN 2017-cod. 2017K55HLC
6 · The paper itself

Abstract

The identification of microRNAs in biological fluids for diagnosis and prognosis is receiving great attention in the field of multiple sclerosis (MS) research but it is still in its infancy. In the present study, we observed in a large sample of MS patients that let-7b-5p levels in the cerebrospinal fluid (CSF) were highly correlated with a number of microRNAs implicated in MS, as well as with a variety of inflammation-related protein factors, showing specific expression patterns coherent with let-7b-5p-mediated regulation. Additionally, we found that the CSF let-7b-5p levels were significantly reduced in patients with the progressive MS compared to patients with relapsing-remitting MS and were negatively correlated with characteristic hallmark processes of the two phases of the disease. Indeed, in the non-progressive phase, let-7b-5p inversely associated with both central and peripheral inflammation; whereas, in progressive MS, the CSF levels of let-7b-5p negatively correlated with clinical disability at disease onset and after a follow-up period. Overall, our results uncovered, by the means of a multidisciplinary approach and multiple statistical analyses, a new possible pleiotropic action of let-7b-5p in MS, with potential utility as a biomarker of MS course.

Indexed as

AdultFemaleHumansInflammationMaleMicroRNAsMiddle AgedMultiple SclerosisMicroRNAsmirnlet7 microRNA, humanExpanded Disability Status Scale (EDSS)G_CSFIL5inflammationlet-7miRNAsmultiple sclerosis (MS)progressive multiple sclerosis (PMS)RANTES

Identifiers

PMID33562569
PMCPMC7915741
OpenAlexW3126346280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.